circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer.

Yun LingGehao LiangQun LinXiaolin FangQing LuoYinghuan CenMaryam MehrpourAhmed HamaiZihao LiuYu ShiJuanmei LiWanyi LinShijie JiaWenqian YangQiang LiuErwei SongJun LiChang Gong

Published in: Molecular cancer (2022)

BC patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
young adults